• 1. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 2. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 3. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 4. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 5. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives Indoles

5-Chloro-6-(Trifluoromethyl)-1H-Indole (CAS No. 1186404-60-3): A Structurally Distinctive Scaffold with Emerging Therapeutic Potential

The compound 5-Chloro-6-(trifluoromethyl)-1H-indole, designated by the Chemical Abstracts Service registry number CAS No. 11864004-60-3, represents a structurally unique indole derivative distinguished by its chlorine substitution at the 5-position and a trifluoromethyl group at the 6-position. This combination of halogen and fluorinated substituents imparts distinctive physicochemical properties, including enhanced lipophilicity and metabolic stability, positioning it as a promising lead compound in drug discovery programs targeting various disease pathways. Recent advancements in synthetic methodologies have enabled scalable production of this compound while maintaining high purity standards required for preclinical and clinical investigations.

5-Chloro-6-(trifluoromethyl)-1H-indole exhibits notable structural versatility due to its planar aromatic system and electron-withdrawing substituents. Computational docking studies published in the Journal of Medicinal Chemistry (2023) revealed its exceptional binding affinity for histone deacetylase 6 (HDAC6), a protein implicated in neurodegenerative diseases. The trifluoromethyl group's ability to form weak halogen bonds with enzyme active sites was identified as a key interaction mechanism, enabling submicromolar inhibitory activity in vitro. This discovery has spurred interest in developing this scaffold as a potential treatment for Alzheimer's disease, where HDAC dysregulation contributes to neuroinflammation and synaptic dysfunction.

In oncology research, this compound has demonstrated dual mechanisms of action through recent studies published in Cancer Research. When tested against triple-negative breast cancer cells, the compound induced apoptosis via mitochondrial pathway activation while simultaneously inhibiting the Wnt/β-catenin signaling cascade – a critical survival pathway for aggressive tumor subtypes. The chlorine substitution at position 5 was shown to enhance cellular uptake compared to non-halogenated analogs, achieving IC?? values of 0.8 μM in MDA-MB-231 xenograft models. These findings align with emerging trends emphasizing multi-targeted therapeutics for cancers resistant to conventional treatments.

Bioisosteric modifications of this core structure are currently explored in anti-inflammatory drug development programs. A 2024 study in Nature Communications demonstrated that substituting the trifluoromethyl group with difluoromethoxy moieties retained COX-2 inhibitory activity while reducing off-target effects on platelet function. The parent scaffold's inherent stability under physiological conditions allows for oral bioavailability exceeding 75% when formulated with cyclodextrin complexes – a critical parameter for chronic inflammatory disease management.

Synthetic chemists have optimized routes leveraging microwave-assisted Suzuki-Miyaura cross-coupling strategies, enabling gram-scale synthesis with >98% purity as reported in Organic Process Research & Development. The reaction sequence employs readily available starting materials: indole derivatives undergo sequential functionalization via NBS chlorination followed by copper-catalyzed trifluoromethylation using CF?I as the electrophilic source. This method reduces process steps by 40% compared to traditional protocols while minimizing hazardous waste generation – addressing both economic and environmental sustainability concerns.

In virology research, this scaffold has emerged as an unexpected inhibitor of SARS-CoV-2 replication through a mechanism distinct from current antivirals. Structural biology studies revealed that the trifluoromethyl group binds within the viral RNA-dependent RNA polymerase's thumb domain, disrupting nucleotide incorporation without inducing resistance mutations observed with remdesivir analogs. Preclinical data published in eLife (2023) showed synergistic antiviral effects when combined with interferon-beta treatment, suggesting potential application during emerging viral outbreaks where combination therapy is critical.

The compound's photophysical properties have also found application in fluorescent probe development for live-cell imaging applications. Conjugation with boron-dipyrromethene (BODIPY) cores created ratiometric sensors capable of detecting intracellular hypochlorite levels – a key biomarker for oxidative stress associated with cardiovascular diseases. The chlorine substitution enhanced photostability under physiological pH conditions, enabling real-time tracking over extended observation periods as reported in Analytical Chemistry.

Ongoing investigations focus on exploiting this scaffold's ability to modulate ion channel activity without affecting voltage-gated sodium channels – a significant advantage over existing epilepsy treatments that cause neurological side effects. Structure-activity relationship studies published in Bioorganic & Medicinal Chemistry Letters identified that substituent orientation relative to the indole plane critically influences GABA_A receptor modulation efficacy, guiding rational design of next-generation anxiolytics.

Safety pharmacology evaluations conducted under Good Laboratory Practice guidelines demonstrated no off-target effects on cardiac ion channels up to 30 mg/kg doses – surpassing regulatory thresholds for clinical advancement according to recent FDA white papers on novel entity submissions. This favorable profile supports progression into Phase I trials targeting orphan indications where current therapies exhibit unacceptable toxicity profiles.

The integration of artificial intelligence-driven ADMET predictions has further accelerated development trajectories for this compound class. Machine learning models trained on >5 million chemical entities successfully predicted blood-brain barrier permeability values matching experimental data within ±0.3 log units – enabling rapid elimination of unfavorable candidates during lead optimization campaigns.

In conclusion, the unique structural features of CAS No. 1186404-60-3 create an ideal platform for developing next-generation therapeutics across diverse therapeutic areas while adhering to modern drug development paradigms emphasizing safety, sustainability, and multifunctional mechanisms of action.

• 104612-21-7(Quinoline, 3-chloro-7-(trifluoromethyl)-)
• 885518-28-5(4,5-dichloro-6-(trifluoromethyl)-1h-indole)
• 866228-56-0(QUINOLINE, 7-CHLORO-4-(TRIFLUOROMETHYL)-)
• 590371-93-0(4-Chloro-3-(trifluoromethyl)quinoline)
• 81565-19-7(3-Chloro-4-(trifluoromethyl)pyridine)
• 49713-56-6(4-Chloro-6-(trifluoromethyl)quinoline)
• 346-55-4(4-Chloro-7-(trifluoromethyl)quinoline)
• 874813-51-1(Acridine, 6,9-dichloro-2-(trifluoromethyl)-)
• 234450-34-1(5,7-Bis(Trifluoromethyl)-4-Chloroquinoline)
• 863111-50-6(1H-INDOLE, 6-CHLORO-5-(TRIFLUOROMETHYL)-)